文献速递MDS 与骨髓增殖性肿瘤

CALR突变骨髓增殖性肿瘤的结局异质性

Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms.
PubMed 文献 · Br J Haematol · 2026-10-07

该研究报告149例CALR突变MPN患者的结局和高危基因组特征。CALR突变ET进展至骨髓纤维化的中位时间为20.4年,20年OS为81%;骨髓纤维化患者中位LFS为12.9年、OS为13.9年。HMR突变与更高的白血病转化、更差的LFS和OS相关,TP53、KRAS和RUNX1突变独立影响LFS和OS。

要点

  • CALR突变MPN结局由体细胞突变而非CALR驱动突变决定
  • HMR突变(含TP53、KRAS、RUNX1)与更差生存相关
  • 无HMR患者疾病进展率极低

核心结论

  • CALR突变MPN的结局由疾病演化中出现的体细胞突变决定,而非CALR驱动突变本身。

研究设计与样本

  • 回顾性报告149例CALR突变MPN患者的结局和高危基因组特征。

主要发现

  • CALR突变ET(n=106)进展至骨髓纤维化(n=40)的中位时间为20.4年,20年OS为81%。
  • 骨髓纤维化患者(n=83)中位LFS为12.9年,OS为13.9年,白血病转化后中位生存6.8个月。
  • HMR突变与显著更高的白血病转化、更差的LFS和OS相关(HR:3.82,95%CI:1.30-11.18),≥2个HMR者结局最差。
  • 独立于MIPSS70-plus v2.0,TP53、KRAS和RUNX1突变分别与更差的LFS和OS相关(HR:2.87,95%CI:1.20-6.88;HR:3.80,95%CI:1.37-10.54;HR:5.61,95%CI:1.53-20.52)。
  • 无HMR患者疾病进展率极低。

关键数值与推荐

  • HMR突变包括ASXL1、EZH2、SRSF2、U2AF1(Q157)、IDH1/2、TP53、SETBP1、KRAS、NRAS和RUNX1,其中后五种未纳入MIPSS70-plus v2.0。

临床怎么用

  • 对CALR突变MPN患者应进行连续分子谱分析以进行风险分层。
  • 携带HMR(包括TP53、KRAS和RUNX1)的患者生存更差,支持考虑早期移植。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Calreticulin gene (CALR) mutations are seen in 25%-30% of myeloproliferative neoplasms (MPNs). We report outcomes and high-risk genomic signatures in 149 patients with CALR-mutated MPN. CALR-mutated essential thrombocythaemia (n = 106) progressed to myelofibrosis (n = 40) at a median of 20.4 years, and 20-year overall survival (OS) was 81%. In 83 patients with myelofibrosis, the median leukaemia-free survival (LFS) was 12.9 years, and OS was 13.9 years. Median survival after leukaemia transformation was 6.8 months. High molecular risk (HMR) mutations included ASXL1, EZH2, SRSF2, U2AF1 (Q157), IDH1/2, TP53, SETBP1, KRAS, NRAS and RUNX1 (later five not included in Mutation-Enhanced International Prognostic Score System [MIPSS70]-plus v2.0); and were associated with a significantly higher leukaemic transformation, inferior LFS and OS (hazard ratio [HR]: 3.82, 95% confidence interval [CI]: 1.30-11.18); with worst outcomes in patients with ≥2 HMR. Independent of MIPSS70-plus v2.0, TP53, KRAS and RUNX1 mutations adversely impacted LFS and OS (HR: 2.87, 95% CI: 1.20-6.88; HR: 3.80, 95% CI: 1.37-10.54; HR: 5.61, 95% CI: 1.53-20.52 respectively). Patients without HMR had a negligible rate of progression. Overall, outcomes are determined not by CALR 'driver' mutation, but by the somatic mutations that can emerge during disease evolution. Hence, serial molecular profiling is important for risk stratification. HMR, including TP53, KRAS and RUNX1, confer inferior survival and support early transplantation consideration.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mawalkar R, Tsai HL, Pasca S, et al. Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms. Br J Haematol. 2026. PMID: 42839864. doi:10.1111/bjh.70859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。